No Data
Subdued Growth No Barrier To Hybio Pharmaceutical Co., Ltd. (SZSE:300199) With Shares Advancing 31%
CICC: Maintains 3SBIO's "Outperform Industry" rating and raises the Target Price to HKD 13.50.
CICC released a Research Report stating that it maintains 3SBIO (01530)'s adjusted Net income for 2025 at 2.407 billion yuan unchanged, introducing an adjusted Net income of 2.602 billion yuan for 2026. The current stock price corresponds to an adjusted P/E of 12.7/11.5 times for 2025/2026. It maintains an outperform rating in the Industry, and due to the recent recovery of liquidity in the Hong Kong stock market and the rise in the valuation center of the Sector, the Target Price is raised by 68.8% to 13.50 Hong Kong dollars, corresponding to an adjusted P/E of 14.0/12.6 times for 2025/2026, implying a 9.9% upside. CICC's main points are as follows: The full-year performance slightly exceeded the bank's expectations for the company, which announced the performance for 2024.
Hybio Pharmaceutical: Performance forecast for the first quarter of 2025.
Hybio Pharmaceutical: 2024 Annual Performance Brief
Hybio Pharmaceutical (300199.SZ): Expected profit of 60 million to 72 million yuan in the first quarter, turning losses into profits year-on-year.
Gelonghui March 26丨Hybio Pharmaceutical (300199.SZ) announced its performance forecast for the first quarter of 2025. From January to March 2025, the company expects to achieve revenue of 0.29 billion yuan - -0.31 billion yuan, an increase of 93.00% - 106.31%; the net income attributable to shareholders of the listed company is expected to be a profit of 60 million yuan - 72 million yuan, compared to a loss of 14.102 million yuan in the same period last year; the net income after deducting non-recurring gains and losses is expected to be a profit of 55 million yuan - 67 million yuan. On December 23, 2024, the company reported liraglutide to the USA Food and Drug Administration.
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Subdued Growth No Barrier To Hybio Pharmaceutical Co., Ltd. (SZSE:300199) With Shares Advancing 28%
